Skip to content

US · ACON · MEDICAL - HEALTHCARE INFORMATION SERVICES

Aclarion, Inc. (ACON) intrinsic value and stock valuation

$1.22as of 2026-11-21 · Mkt cap 1.26M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aclarion, Inc. DCF and intrinsic value

InvestorsCraft values ACON with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ACON’s statements →

Aclarion, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services Broomfield, CA 80021 aclarion.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$80K+9.9% 5y CAGRd
20192025
Net income
-$-7.23M
20192025
Free cash flow
-$-7.19M
20192025
Total equity
$12.8M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$80K$50K$80K$60K$60K
Operating income-$-7.05M-$-5.51M-$-4.88M-$-5.56M-$-2.95M
Net income-$-7.23M-$-6.99M-$-4.91M-$-7.07M-$-4.95M
EPSd-$-13.64M————
Operating cash flow-$-7.16M-$-5.27M-$-3.65M-$-4.95M-$-2.35M
Capital expenditure-$-20K-$-320K-$-120K-$-210K-$0.00
Free cash flow-$-7.19M-$-5.59M-$-3.77M-$-5.16M-$-2.35M
Total assets$13.7M$2.12M$2.46M$2.91M$1.89M
Total debt$0.00$0.00$1.13M$0.00$2M
Net debt-$-12.02M-$-450K$100K-$-1.47M$1.57M
Total equity$12.8M$970K-$-730K$2.23M-$-5.73M
Cash and short-term investments$12M$450K$1.02M$1.47M$430K
Income statement
20252024202320222021
Revenue$80K$50K$80K$60K$60K
Cost of revenue$300K$130K$80K$70K$70K
Gross profit-$-220K-$-80K-$0.00-$0.00-$-10K
Research and development expenses$1.03T$890K$870K$1.07M$790K
Selling, general and administrative expenses$6.03T$4.59M$4M$4.49M$2.16M
Other expenses-$-7.06T-$-50K$0.00$0.00$0.00
Operating expenses$6.83M$5.43M$4.88M$5.56M$2.94M
Cost and expenses$7.13M$5.56M$4.95M$5.62M$3.01M
Interest income$410K$0.00$0.00$0.00$0.00
Interest expense$0.00$540K$610K$1.51M$480K
Depreciation and amortization$230K$190K$160K$140K$190K
Ebitda-$-7.01M-$-6.26M-$-4.14M-$-5.42M-$-4.29M
Operating income-$-7.05M-$-5.51M-$-4.88M-$-5.56M-$-2.95M
Total other income/expenses, net-$-180K-$-1.48M-$-40K-$-1.51M-$-2M
Income before tax-$-7.23M-$-6.99M-$-4.91M-$-7.07M-$-4.95M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-7.23M-$-6.99M-$-4.91M-$-7.07M-$-4.95M
Weighted average shares outstanding$530K$0.00$0.00$0.00$0.00
Weighted average diluted shares outstanding$530K$0.00$0.00$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$12M$450K$1.02M$1.47M$430K
Net receivables$30K$20K$10K$20K$10K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$12.4M$820K$1.29M$1.7M$730K
Property, plant and equipment, net$20K$10K$0.00$0.00$10K
Goodwill and intangible assets$1.25M$1.29M$1.17M$1.21M$1.14M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.28M$1.3M$1.17M$1.21M$1.16M
Total assets$13.7M$2.12M$2.46M$2.91M$1.89M
Accounts payable$320K$530K$760K$460K$1.06M
Short-term debt$0.00$0.00$1.13M$0.00$2M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$840K$1.15M$3.19M$690K$7.62M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$840K$1.15M$3.19M$690K$7.62M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-58.5M-$-51.26M-$-44.28M-$-39.37M-$-31.89M
Accumulated other comprehensive income (loss)$0.00-$0.00$0.00$0.00$0.00
Total equity$12.8M$970K-$-730K$2.23M-$-5.73M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$1.13M$0.00$2M
Net debt-$-12.02M-$-450K$100K-$-1.47M$1.57M
Cash flow statement
20252024202320222021
Net income-$-7.23M-$-6.99M-$-4.91M-$-7.07M-$-4.95M
Depreciation and amortization$230K$190K$160K$140K$190K
Stock-based compensation$110K$290K$460K$1.29M$180K
Change in working capital-$-360K-$-560K$620K-$-620K$680K
Accounts receivable-$-10K$10K-$0.00-$-10K$20K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-200K-$-160K$220K-$-600K$200K
Net cash provided by operating activities-$-7.16M-$-5.27M-$-3.65M-$-4.95M-$-2.35M
Investments in property, plant and equipment-$-200K-$-320K-$-120K-$-210K-$-150K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-200K-$-320K-$-120K-$-210K-$-150K
Common stock issued$20.2M$5.57M$1.46M$8.55M$0.00
Common stock repurchased-$-1.21M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$19M$5.03M$3.31M$6.19M$2.94M
Net change in cash$11.6M-$-570K-$-450K$1.03M$440K
Cash at end of period$12M$460K$1.03M$1.48M$450K
Operating cash flow-$-7.16M-$-5.27M-$-3.65M-$-4.95M-$-2.35M
Capital expenditure-$-20K-$-320K-$-120K-$-210K-$0.00
Free cash flow-$-7.19M-$-5.59M-$-3.77M-$-5.16M-$-2.35M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aclarion, Inc.

        Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.

        CEO
        Brent Ness
        Employees
        11
        Beta
        1.21

        Explore

        Frequently asked questions

        What is the intrinsic value of Aclarion, Inc. (ACON)?

        InvestorsCraft does not currently publish an intrinsic value for ACON. How the IC value is calculated.

        Is ACON undervalued?

        InvestorsCraft does not publish an undervaluation signal for ACON at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.